Cross-sectional assessment of mild cognitive impairment in pre-dialysis chronic kidney disease and its association with inflammation and changes seen on MRI: what the eyes cannot see / Avaliação transversal do comprometimento cognitivo leve em doença renal crônica pré-dialítica e associação com inflamação e alterações na ressonância magnética: o que os olhos não veem

Abstract Introduction: Mild cognitive impairment (MCI) is a prevalent and underdiagnosed condition in chronic kidney disease (CKD), that shares common pathophysiological factors such as chronic inflammation. Objective: To evaluate the association of MCI in CKD stages 1-5 using inflammatory markers and changes by magnetic resonance imaging (MRI). Patients and Methods: Cross-sectional study in adult patients with pre-dialysis CKD. MCI was assessed by the Montreal Cognitive Assessment (MoCA) and the estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration equation. Sociodemographic and clinical data were collected from medical records. The cytokines IL-4, IL-6, IL-17, TNF-α and hs-CRP were determined. Brain MRI was performed in a 1.5 Tesla device, without paramagnetic contrast. A descriptive analysis followed by a comparison of abnormal versus normal MoCA scores among all studied variables. A linear regression analysis was performed using MoCA as a dependent variable, adjusted for confounding factors. Results: Of 111 invited patients, eighty completed the neuropsychological assessment and 56 underwent MRI, and were included in the study. Mean age was 56.3 ± 8.3 years and 51.8% (n = 29) had altered MoCA. When compared to the group with normal MoCA, the group with altered MoCA had higher levels of IL-6 and IL-17. There was no correlation between altered MoCA with eGFR or with MRI abnormalities. Conclusão: MCI assessed by MoCA was prevalent in patients with pre-dialysis CKD, it was associated with inflammation and showed no correlation with MRI changes.

Resumo Introdução: O comprometimento cognitivo leve (CCL) é prevalente e subdiagnosticado na doença renal crônica (DRC), condição com a qual compartilha fatores fisiopatológicos como a inflamação crônica. Objetivo: Avaliar a associação do CCL na DRC estágios 1 a 5, com marcadores inflamatórios e alterações de exames de imagem por ressonância magnética (RM). Pacientes e métodos: Estudo transversal em pacientes adultos, com DRC pré-dialítica. CCL foi avaliado pelo Montreal Cognitive Assessment (MoCA) e a taxa de filtração glomerular estimada (TFGe), pela equação do CKD-EPI. Dados sociodemográficos e clínicos foram coletados nos prontuários médicos. Dosadas citocinas IL-4, IL-6, IL-17, o TNF-α e PCR-us. A RM do encéfalo foi realizada em aparelho de 1,5 Tesla, sem contraste. Realizada análise descritiva seguida por comparação de pontuações do MoCA anormais versus normais entre todas as variáveis estudadas. A regressão linear foi realizada usando MoCA como uma variável dependente, ajustada para fatores de confusão. Resultados: De 111 pacientes convidados, oitenta completaram a avaliação neuropsicológica, 56 realizaram RM, tendo sido incluídos no estudo. A média de idade foi de 56,3 ± 8,3 anos e 51,8% (n = 29) apresentavam MoCA alterado. Quando comparado ao grupo MoCA normal, o grupo MoCA alterado apresentou níveis mais elevados de IL-6 e IL-17. Não houve correlação entre MoCA alterado com TFGe nem com anormalidades na RM. Nos modelos ajustados, a IL-6 foi preditor independente do MoCA alterado Conclusão: O CCL avaliado pelo MoCA foi prevalente em pacientes com DRC pré-dialítica, associou-se com inflamação e não apresentou correlação com alterações da RM.

Three years evaluation of peritoneal dialysis and hemodialysis absorption costing: perspective of the service provider compared to funds transfers from the public and private healthcare systems / Três anos de avaliação do custeio por absorção da diálise peritoneal e hemodiálise: perspectiva do prestador de serviços em comparação com o repasse de recursos dos sistemas de saúde público e privado

Abstract Introduction: 72% of renal replacement therapy (RRT) clinics in Brazil are private. However, regarding payment for dialysis therapy, 80% of the patients are covered by the Unified Health System (SUS) and 20% by private healthcare (PH). Objectives: To evaluate costs for peritoneal dialysis (PD) and hemodialysis (HD) from the perspective of the service provider and compare with fund transfers from SUS and private healthcare. Methods: The absorption costing method was applied in a private clinic. Study horizon: January 2013 - December 2016. Analyzed variables: personnel, medical supplies, tax expenses, permanent assets, and labor benefits. The input-output matrix method was used for analysis. Results: A total of 27,666 HD sessions were performed in 2013, 26,601 in 2014, 27,829 in 2015, and 28,525 in 2016. There were 264 patients on PD in 2013, 348 in 2014, 372 in 2015, and 300 in 2016. The mean monthly cost of the service provider was R$ 981.10 for a HD session for patients with hepatitis B; R$ 238.30 for hepatitis C; R$197.99 for seronegative patients; and R$ 3,260.93 for PD. Comparing to fund transfers from SUS, absorption costing yielded a difference of -269.7% for hepatitis B, +10.2% for hepatitis C, -2.0% for seronegative patients, and -29.8% for PD. For PH fund transfers, absorption costing for hepatitis B yielded a difference of -50.2%, +64.24% for hepatitis C, +56.27% for seronegative patients, and +48.26 for PD. Conclusion: The comparison of costs of dialysis therapy from the perspective of the service provider with fund transfers from SUS indicated that there are cost constraints in HD and PD.

Resumo Introdução: 72% das clínicas de terapia renal substitutiva (TRS) no Brasil são privadas. Entretanto, quanto ao pagamento da terapia dialítica, o Sistema Único de Saúde (SUS) cobre 80% dos pacientes e, a saúde privada (SP), 20%. Objetivos: Avaliar custos de diálise peritoneal (DP) e hemodiálise (HD) na perspectiva do prestador de serviços, comparando com repasses do SUS e saúde suplementar. Métodos: O método de custeio por absorção foi aplicado em clínica privada. Horizonte de estudo: Janeiro 2013 - Dezembro 2016. Variáveis analisadas: pessoal, suprimentos médicos, despesas tributárias, ativos permanentes, benefícios trabalhistas. Utilizou-se para análise o método da matriz de input-output. Resultados: Realizou-se um total de 27.666 sessões de HD em 2013, 26.601 em 2014, 27.829 em 2015, e 28.525 em 2016. Havia 264 pacientes em DP em 2013, 348 em 2014, 372 em 2015, e 300 em 2016. O custo médio mensal do prestador de serviços foi R$ 981,10 por sessão de HD para pacientes com hepatite B; R$ 238,30 para hepatite C; R$ 197,99 para pacientes soronegativos; R$ 3.260,93 para DP. Em comparação com repasses do SUS, o custeio por absorção mostrou uma diferença de -269,7% para hepatite B, +10,2% para hepatite C, -2,0% para pacientes soronegativos, e -29,8% para DP. Para repasses da SP, o custeio por absorção para hepatite B mostrou uma diferença de -50,2%, +64,24% para hepatite C, +56,27% para pacientes soronegativos, e +48,26 para DP. Conclusão: A comparação de custos da terapia dialítica da perspectiva do prestador de serviços com os repasses do SUS indicou que existem restrições de custos em HD e DP.

Cross-sectional assessment of mild cognitive impairment in pre-dialysis chronic kidney disease and its association with inflammation and changes seen on MRI: what the eyes cannot see.

INTRODUCTION: Mild cognitive impairment (MCI) is a prevalent and underdiagnosed condition in chronic kidney disease (CKD), that shares common pathophysiological factors such as chronic inflammation. OBJECTIVE: To evaluate the association of MCI in CKD stages 1-5 using inflammatory markers and changes by magnetic resonance imaging (MRI). PATIENTS AND METHODS: Cross-sectional study in adult patients with pre-dialysis CKD. MCI was assessed by the Montreal Cognitive Assessment (MoCA) and the estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration equation. Sociodemographic and clinical data were collected from medical records. The cytokines IL-4, IL-6, IL-17, TNF-α and hs-CRP were determined. Brain MRI was performed in a 1.5 Tesla device, without paramagnetic contrast. A descriptive analysis followed by a comparison of abnormal versus normal MoCA scores among all studied variables. A linear regression analysis was performed using MoCA as a dependent variable, adjusted for confounding factors. RESULTS: Of 111 invited patients, eighty completed the neuropsychological assessment and 56 underwent MRI, and were included in the study. Mean age was 56.3 ± 8.3 years and 51.8% (n = 29) had altered MoCA. When compared to the group with normal MoCA, the group with altered MoCA had higher levels of IL-6 and IL-17. There was no correlation between altered MoCA with eGFR or with MRI abnormalities. CONCLUSÃO: MCI assessed by MoCA was prevalent in patients with pre-dialysis CKD, it was associated with inflammation and showed no correlation with MRI changes.

Three years evaluation of peritoneal dialysis and hemodialysis absorption costing: perspective of the service provider compared to funds transfers from the public and private healthcare systems.

INTRODUCTION: 72% of renal replacement therapy (RRT) clinics in Brazil are private. However, regarding payment for dialysis therapy, 80% of the patients are covered by the Unified Health System (SUS) and 20% by private healthcare (PH). OBJECTIVES: To evaluate costs for peritoneal dialysis (PD) and hemodialysis (HD) from the perspective of the service provider and compare with fund transfers from SUS and private healthcare. METHODS: The absorption costing method was applied in a private clinic. Study horizon: January 2013 - December 2016. Analyzed variables: personnel, medical supplies, tax expenses, permanent assets, and labor benefits. The input-output matrix method was used for analysis. RESULTS: A total of 27,666 HD sessions were performed in 2013, 26,601 in 2014, 27,829 in 2015, and 28,525 in 2016. There were 264 patients on PD in 2013, 348 in 2014, 372 in 2015, and 300 in 2016. The mean monthly cost of the service provider was R$ 981.10 for a HD session for patients with hepatitis B; R$ 238.30 for hepatitis C; R$197.99 for seronegative patients; and R$ 3,260.93 for PD. Comparing to fund transfers from SUS, absorption costing yielded a difference of -269.7% for hepatitis B, +10.2% for hepatitis C, -2.0% for seronegative patients, and -29.8% for PD. For PH fund transfers, absorption costing for hepatitis B yielded a difference of -50.2%, +64.24% for hepatitis C, +56.27% for seronegative patients, and +48.26 for PD. CONCLUSION: The comparison of costs of dialysis therapy from the perspective of the service provider with fund transfers from SUS indicated that there are cost constraints in HD and PD.

Multidisciplinary treatment for patients with chronic kidney disease in pre-dialysis minimizes costs: a four-year retrospective cohort analysis / O tratamento multidisciplinar para pacientes com doença renal crônica em pré-diálise minimiza os custos: uma análise de coorte retrospectiva de quatro anos

Abstract Introduction: Chronic kidney disease (CKD) can progress to end-stage renal disease (ESRD), and clinical studies show that this progression can be slowed. The objective of this study was to estimate the costs to Brazil's public health system (SUS) throughout the course of CKD in the pre-dialysis stage compared to the costs to the SUS of dialysis treatment (DT). Methods: A retrospective cohort study was conducted to analyze clinical and laboratory variables; the outcome analyzed was need for DT. To assess cost, a microcosting survey was conducted according to the Methodological Guidelines for Economic Evaluations in Healthcare and the National Program for Cost Management, both recommended by the Brazilian Ministry of Health for economic studies. Results: A total of 5,689 patients were followed between 2011 and 2014, and 537 met the inclusion criteria. Average costs increased substantially as the disease progressed. The average cost incurred in stage G1 in Brazilian reals was R$ 7,110.78, (US$1,832.06) and in stage G5, it was R$ 26,814.08 (US$6,908.53), accumulated over the four years. Conclusion: A pre-dialysis care program may reduce by R$ 33,023.12 ± 1,676.80 (US$ 8,508.26 ± 432.02) the average cost for each year of DT avoided, which is sufficient to cover the program's operation, minimizing cost. These results signal to public health policy makers the real possibility of achieving significant cost reduction in the medium term for CKD care (4 years), to a program that disbursed R$ 24 billion (US$ 6.8 billion) for DT in Brazil between 2009 and 2018.

Resumo Introdução: Doença renal crônica (DRC) pode progredir para doença renal estágio terminal (DRET). Estudos clínicos mostram que esta progressão pode ser retardada. Objetivo: estimar custos para o sistema público de saúde (SUS) do Brasil durante o curso da DRC no estágio pré-diálise, comparado com os custos para o SUS do tratamento dialítico (TD). Métodos: Conduziu-se estudo de coorte retrospectivo para analisar variáveis clínicas e laboratoriais; o desfecho analisado foi a necessidade de TD. Para avaliar os custos, realizou-se pesquisa de microcustos de acordo com as Diretrizes Metodológicas para Avaliações Econômicas em Saúde e o Programa Nacional de Gestão de Custos, ambos recomendados pelo Ministério da Saúde Brasileiro para estudos econômicos. Resultados: Acompanhou-se um total de 5.689 pacientes entre 2011-2014; 537 preencheram os critérios de inclusão. Os custos médios aumentaram substancialmente à medida que a doença progrediu. O custo médio incorrido no estágio G1 em reais foi R$ 7.110,78 (US$ 1.832,06) e no estágio G5 foi R$ 26.814,08 (US$ 6.908,53), acumulado durante os quatro anos. Conclusão: Um programa de atendimento pré-dialítico pode reduzir em R$ 33.023,12 ± 1.676,80 (US$ 8.508,26 ± 432,02) o custo médio para cada ano de TD evitado. Isso é suficiente para cobrir a operação do programa, minimizando custos. Estes resultados sinalizam aos formuladores de políticas de saúde pública a possibilidade real de alcançar redução significativa de custos em médio prazo para o cuidado da DRC (4 anos), para um programa que desembolsou R$ 24 bilhões (US$ 6,8 bilhões) para TD no Brasil entre 2009-2018.

Multidisciplinary treatment for patients with chronic kidney disease in pre-dialysis minimizes costs: a four-year retrospective cohort analysis.

INTRODUCTION: Chronic kidney disease (CKD) can progress to end-stage renal disease (ESRD), and clinical studies show that this progression can be slowed. The objective of this study was to estimate the costs to Brazil's public health system (SUS) throughout the course of CKD in the pre-dialysis stage compared to the costs to the SUS of dialysis treatment (DT). METHODS: A retrospective cohort study was conducted to analyze clinical and laboratory variables; the outcome analyzed was need for DT. To assess cost, a microcosting survey was conducted according to the Methodological Guidelines for Economic Evaluations in Healthcare and the National Program for Cost Management, both recommended by the Brazilian Ministry of Health for economic studies. RESULTS: A total of 5,689 patients were followed between 2011 and 2014, and 537 met the inclusion criteria. Average costs increased substantially as the disease progressed. The average cost incurred in stage G1 in Brazilian reals was R$ 7,110.78, (US$1,832.06) and in stage G5, it was R$ 26,814.08 (US$6,908.53), accumulated over the four years. CONCLUSION: A pre-dialysis care program may reduce by R$ 33,023.12 ± 1,676.80 (US$ 8,508.26 ± 432.02) the average cost for each year of DT avoided, which is sufficient to cover the program's operation, minimizing cost. These results signal to public health policy makers the real possibility of achieving significant cost reduction in the medium term for CKD care (4 years), to a program that disbursed R$ 24 billion (US$ 6.8 billion) for DT in Brazil between 2009 and 2018.

Screening of family members of chronic kidney disease patients with Fabry disease mutations: a very important and underrated task / Triagem de familiares de pacientes com doença renal crônica com mutação na doença de Fabry: uma tarefa muito importante e subestimada

ABSTRACT Introduction: Fabry disease is a chronic, progressive, and multi-system hereditary condition, related to an Xq22 mutation in X chromosome, which results in deficiency of alpha-galactosidase enzyme, hence reduced capacity of globotriaosylceramide degradation. Objectives: to evaluate the prevalence of Fabry disease (FD) mutations, as well as its signs and symptoms, among relatives of chronic kidney disease (CKD) patients diagnosed with FD during a previously conducted study, named "Clinical and epidemiological analysis of Fabry disease in dialysis centers in Brazil". Methods: a cross-sectional study was carried out, and data was collected by interviewing the relatives of patients enrolled in the Brazil Fabry Kidney Project and blood tests for both Gb3 dosage and genetic testing. Results: Among 1214 interviewed relatives, 115 (9.47%) were diagnosed with FD, with a predominance of women (66.10%). The most prevalent comorbidities were rheumatologic conditions and systemic hypertension (1.7% each), followed by heart, neurological, cerebrovascular diseases, and depression in 0.9% of individuals. Intolerance to physical exercise and tiredness were the most observed symptoms (1.7%), followed by periodic fever, intolerance to heat or cold, diffuse pain, burn sensation or numbness in hands and feet, reduced or absent sweating, as well as abdominal pain after meals in 0.9%. Conclusion: We found a prevalence of Fabry disease in 9.47% of relatives of CKD patients with this condition, remarkably with a 66.1% predominance of women, which contrasts with previous reports. The screening of family members of FD patients is important, since it can lead to early diagnosis and treatment, thus allowing better quality of life and improved clinical outcomes for these individuals.

RESUMO Introdução: A doença de Fabry é uma condição hereditária crônica, progressiva e multissistêmica, relacionada a uma mutação Xq22 no cromossomo X, que resulta em deficiência da enzima alfa-galactosidase, diminuindo a capacidade de degradação da globotriaosilceramida. Objetivos: avaliar a prevalência de mutações na doença de Fabry, bem como seus sinais e sintomas, em familiares de pacientes com doença renal crônica (DRC) diagnosticados com DF durante um estudo realizado anteriormente, denominado "Análise clínica e epidemiológica da doença de Fabry em centros de diálise no Brasil". Métodos: foi realizado um estudo transversal e os dados foram coletados através da entrevista com familiares de pacientes inscritos no Projeto Rim Fabry Brasil e exames de sangue para dosagem de Gb3 e testes genéticos. Resultados: Dos 1,214 familiares entrevistados, 115 (9,47%) foram diagnosticados com DF, com predomínio de mulheres (66,10%). As comorbidades mais prevalentes foram condições reumatológicas e hipertensão arterial sistêmica (1,7% cada), seguidas por doenças cardíacas, neurológicas, cerebrovasculares e depressão em 0,9% dos indivíduos. Intolerância ao exercício físico e cansaço foram os sintomas mais observados (1,7%), seguidos de febre periódica, intolerância ao calor ou ao frio, dor difusa, sensação de queimação ou dormência nas mãos e nos pés, sudorese reduzida ou ausente, além de dor abdominal após refeições em 0,9%. Conclusão: Encontramos uma prevalência da doença de Fabry em 9,47% dos familiares de pacientes com DRC com essa condição, notadamente com uma predominância de 66,1% de mulheres, o que contrasta com relatos anteriores. A triagem de familiares de pacientes com DF é importante, pois pode levar ao diagnóstico e tratamento precoces, permitindo melhor qualidade de vida e melhores resultados clínicos para esses indivíduos.

Screening of family members of chronic kidney disease patients with Fabry disease mutations: a very important and underrated task.

INTRODUCTION: Fabry disease is a chronic, progressive, and multi-system hereditary condition, related to an Xq22 mutation in X chromosome, which results in deficiency of alpha-galactosidase enzyme, hence reduced capacity of globotriaosylceramide degradation. OBJECTIVES: to evaluate the prevalence of Fabry disease (FD) mutations, as well as its signs and symptoms, among relatives of chronic kidney disease (CKD) patients diagnosed with FD during a previously conducted study, named "Clinical and epidemiological analysis of Fabry disease in dialysis centers in Brazil". METHODS: a cross-sectional study was carried out, and data was collected by interviewing the relatives of patients enrolled in the Brazil Fabry Kidney Project and blood tests for both Gb3 dosage and genetic testing. RESULTS: Among 1214 interviewed relatives, 115 (9.47%) were diagnosed with FD, with a predominance of women (66.10%). The most prevalent comorbidities were rheumatologic conditions and systemic hypertension (1.7% each), followed by heart, neurological, cerebrovascular diseases, and depression in 0.9% of individuals. Intolerance to physical exercise and tiredness were the most observed symptoms (1.7%), followed by periodic fever, intolerance to heat or cold, diffuse pain, burn sensation or numbness in hands and feet, reduced or absent sweating, as well as abdominal pain after meals in 0.9%. CONCLUSION: We found a prevalence of Fabry disease in 9.47% of relatives of CKD patients with this condition, remarkably with a 66.1% predominance of women, which contrasts with previous reports. The screening of family members of FD patients is important, since it can lead to early diagnosis and treatment, thus allowing better quality of life and improved clinical outcomes for these individuals.

Aspectos psicossociais da gestação de alto risco: análise de mulheres grávidas hospitalizadas / Psychosocial aspects of high-risk pregnancy: analysis of hospitalized pregnant women / Aspectos psicosociales de la gestación de alto riesgo: análisis de mujeres embarazadas hospitalizadas

A gestação de alto risco é caracterizada por ser um momento em que a vida ou a saúde da mãe e/ou do feto e/ou do recém-nascido está submetida a maiores chances de morte que a média da população considerada. O estudo objetivou apresentar dados sobre o perfil de gestantes de alto risco e identificar os aspectos psicossociais ligados à gravidez. A amostra foi composta por 74 mulheres grávidas em um hospital no município de Juiz de Fora, MG. Elas responderam ao PHQ-2, a EPSS, ao IDATE, ao ASSIST e a um questionário sociodemográfico e clínico. Foi possível observar a prevalência de sintomas de depressão, ansiedade, baixo suporte social e uso de substâncias na população avaliada. As análises confirmaram correlações entre características sociodemográficas, clínicas e aspetos psicossociais. Os resultados demonstram a relevância de se conhecer o perfil dessas mulheres para a melhora na elaboração de estratégias de suporte direcionadas ao enfrentamento de possíveis fatores que possam interferir no bom andamento da gestação.

The high-risk pregnancy is characterized for being a moment that the life or health of the mother and/or fetus and/or newborn is subjected to higher risks of death compared to the average population. The study aimed to present data concerning the profile of high risks pregnancy and determine psychosocial aspects about high-risk. The sample was composed by 74 pregnant women in a hospital located in Juiz de Fora/MG, Brazil. The instruments applied were: PHQ-2, PSSS, STAI, ASSIST and a sociodemographic and clinical survey. It was possible to identify the prevalence of depressive symptoms, anxiety, reduced social support and inappropriate substance use in this population. The analyzes confirmed correlations between sociodemographic, clinical, and psychosocial aspects. The results demonstrate the relevance of knowing the profile of these women to improve the formulation of supportive strategies, directing to confront possible factors that may interfere the good progress of the gestation.

La gestación de alto riesgo se caracteriza por ser un momento que la vida o la salud de la madre y/o del feto está sometida a mayores riesgos de la muerte que la media de la población considerada. El estudio objetivó presentar datos sobre el perfil de gestantes de alto riesgo e identificar los aspectos psicosociales ligados al embarazo de riesgo. Se realizó con 74 mujeres clasificadas en el perfil de gestación de alto riesgo en un hospital en el municipio de Juiz de Fora / MG. Ellas respondieron al PHQ-2, a la EPSS, al IDATE, al ASSIST y a un cuestionario sociodemográfico y clínico. Los análisis confirmaron correlaciones entre características sociodemográficas, clínicas y aspectos psicosociales. Los resultados demuestran la relevancia de conocer el perfil de esas mujeres para mejorar en la elaboración de estrategias de soporte dirigidas al enfrentamiento de factores que puedan interferir en el buen andamiento de la gestación.

Pharmacotherapy assessment in chronic kidney disease: validation of the PAIR instrument for use in Brazil.

Individuals with chronic kidney disease (CKD) use polypharmacy, which, in combination with renal impairment, exposes them to the risk of drug-related problems (DRPs). There are no available tools in Brazil to systematically assess the pharmacotherapy and management of DRPs in this population. Therefore, the objective of this work was to validate the PAIR instrument (Pharmacotherapy Assessment in Chronic Renal Disease) for use in Brazilian Portuguese. This is a retrospective longitudinal observational study. Medical records from 100 CKD patients under conservative treatment, between 2016 and 2017, in a nephrology clinic, were analyzed. PAIR was applied by pharmacists in two consultations of the same patient, with an interval of 6 months. Reliability, conceptual validity, responsiveness of the instrument and prevalence of DRPs in the studied sample were assessed. A mean of 1.26 ± 0.96 DRPs/patient was identified. Inter-rater reliability coefficients (k) ranged from 0.58 to 0.94 and from 0.79 to 1.00 for test-retest, revealing moderate to perfect level of agreement. In conceptual validity, a mean of 1.60 ± 1.24 DRPs/patient was identified by the nephrologist through clinical judgment, compared to 1.33±0.76 DRPs/patient identified by the pharmacist using PAIR (p = 0.07). Therefore PAIR allowed the identification of clinically significant DRPs. In responsiveness, a mean of 1.26 ± 0.96 DRPs/patient was identified at the first consultation and 1.11 ± 1.02 DRPs/patient at the subsequent consultation (p = 0.17) by the pharmacist using PAIR. The number of DRPs between the periods did not change. As a conclusion, the PAIR allowed the identification of clinically significant DRPs in CKD, constituting a new validated instrument to be used in Brazil.

A narrative review of the impacts of income, education, and ethnicity on arterial hypertension, diabetes mellitus, and chronic kidney disease in the world.

Nontransmissible chronic diseases (NTCDs) are the leading causes of death worldwide, causing serious social and economic consequences in all societies and economies and emerging as a major public health problem. One of the ways of coping the social and economic impact caused by the NTCDs is the elaboration of effective public policies; one of the instruments used for the elaboration of public policies is the social indicators. The most popular indicator at present is the Human Development Index (HDI), which covers the dimensions of longevity, education, and income. The Inequality-adjusted HDI (IHDI) was implemented that quantifies the effects of inequality in development, measured in terms of HDI. The objective of the present study was to analyze the impact of income, education, and ethnicity in hypertension, diabetes mellitus (DM), and chronic kidney disease (CKD) in the world, through the narrative review of the literature and analyzing the social indicators HDI and IHDI of the countries analyzed. After analyzing 161 studies from 96 countries, we identified that income, education, and color impact on the prevalence, incidence, diagnosis, treatment, progression, and mortality of hypertension, DM, and CKD in both low- and middle-income countries' development, as well as high and very high human development. The HDI data for all countries change when adjusted for inequality. The theme related to social factors needs to be a constant in the elaboration of health policies, as well as present in the professional doing.

Estudos de custo sobre terapia dialítica no mundo: uma revisão sistemática e uma abordagem histórica / Cost studies on dialysis therapy in the world: a systematic review and a historical approach

Introdução: A doença renal afeta 850 milhões de pessoas no mundo e é uma das principais contribuintes para a carga global de doenças não transmissíveis (DNT). Projeta-se que até 2040 seja a quinta causa de anos de vida perdidos. Objetivo: Avaliar onde (geograficamente) e como estão sendo feitos os estudos de custo em terapia dialítica no mundo. Material e métodos: Foi realizada nos dias 26/06/2017, 10/07/2017 e 30/09/2018 uma busca com os unitermos "cost and cost analysis", "health expenditures" and "peritoneal dialysis", os mesmos unitermos e "renal dialysis" nas bases Pubmed, Scielo e EmBase e foram encontrados 1796 artigos, destes foram selecionados 124. Acrescentou-se análise no Google Acadêmico. Ao final, analisou-se 125 artigos. Os critérios de inclusão dos artigos foram terem como escopo do estudo o custo, utilizando metodologias diversas como custo, custo total, custo efetividade, custo utilidade, custo benefício, custo minimização, gasto, impacto econômico. A perspectiva poderia ser do pagador e do prestador de serviço. Resultados: Observou-se um maior número de publicações a partir do ano 2000. Com relação ao desenho dos estudos, a maioria apresentou metodologia de difícil reprodutibilidade, utilizando conceitos variados e métodos diversos. Há uma grande variabilidade do custo entre os países e até mesmo entre os centros de diálise. Em linhas gerais, em países de alta renda, a DPAC (diálise peritoneal ambulatorial contínua) e a DPA (diálise peritoneal automatizada) apresentam menor custo quando comparadas à HD (hemodiálise). No Brasil a maioria dos estudos mostra HD apresentando menor custo que DPAC e DPA. Os desenhos são diversos e mostram, em geral, a perspectiva do pagador. Conclusão: Estudos de custos são recentes na literatura, incluem métodos diversos e a descrição dos resultados não é padronizada. Esperamos progredir para uma discussão da saúde baseada em valor.

Introduction: Kidney disease affects 850 million people worldwide and is a major contributor to the global burden of noncommunicable diseases (NCDs). By 2040 it is projected to be the fifth cause of lost years of life. Objective:The aim of this review is to evaluate where (geographically) and how cost studies on dialysis therapy are being done in the world. Material and methods: A search was carried out on 06/26/2017, 07/10/2017 and 09/30/2018 with the keywords "cost and cost analysis", "health expenditures" and "peritoneal dialysis". The same keywords and "renal dialysis" in Pubmed, Scielo and EmBase databases and 1796 articles were found, of which 124 were selected. We added analysis in academic google. At the end we analyzed 125 articles. The inclusion criteria of the articles were the scope of the study cost, using various methodologies such as cost, total cost, cost effectiveness, cost utility, cost benefit, cost minimization, expense, economic impact. The perspective could be from the payer and the service provider. Results:We observed a greater number of publications from the year 2000. Regarding the design of the studies, most presented a difficult to reproduce methodology with different concepts and different method. There were great variability across countries and even between dialysis centers. Overall, in high-income countries, continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) are less expensive than HD (hemodialysis). In Brazil most studies show HD presenting lower cost than CAPD and APD. Conclusion: Cost studies are recent in the literature, include several methods and the description of the results is not standardized. The designs are diverse and generally show the perspective of the payer. We hope to progress to a value-based health discussion.

Rectus femoris muscle mass evaluation by ultrasound: facilitating sarcopenia diagnosis in pre-dialysis chronic kidney disease stages.

OBJECTIVES: We evaluated the validity and reliability of ultrasonography measurement of rectus femoris cross-sectional area compared to computed tomography in patients in pre-dialysis chronic kidney disease and analyzed the association between these measurements and the diagnosis of sarcopenia. METHODS: One hundred patients with nondialysis chronic kidney disease were evaluated. Sarcopenia was defined using the criteria of the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). The rectus femoris cross-sectional area was evaluated using ultrasonography and computed tomography. RESULTS: The prevalence of sarcopenia was 29% according to the FNIH criteria. The difference in mean rectus femoris cross-sectional area by ultrasonography and computed tomography was 3.97 mm, with a strong correlation between the two methods (p<0.001). Bland-Altman plot analysis showed good agreement between computed tomography and ultrasonography. Rectus femoris cross-sectional area was significantly correlated with muscle strength (r=0.300, p=0.002), lean body mass in the upper limbs (r=0.286, p=0.004), and lean body mass in the lower limbs (r=0.271, p=0.006). The prevalence of sarcopenia was 12% (n=12) based on the definition of low muscle mass according to ultrasonography of the rectus femoris cross-sectional area. CONCLUSION: Ultrasonography was demonstrated to be a valid and reliable method for evaluating the rectus femoris cross-sectional area in patients in pre-dialysis chronic kidney disease.

Validated registry of pre-dialysis chronic kidney disease: description of a large cohort.

INTRODUCTION: Chronic diseases account for the majority of deaths in Brazil. These include hypertension (SAH) and diabetes mellitus (DM), which are the main causes of chronic kidney disease (CKD). OBJECTIVE: This study aimed to validate the data of an electronic health record and to point out characteristics of the profile of these users in relation to clinical quality indicators for a pre-dialytic CKD. METHODS: Retrospective cohort, August/2010 to December/2014. Included users > 18 years, with at least two queries. Variables analyzed: sociodemographic, underlying disease, main medications and main clinical indicators of control. A descriptive analysis was performed and the percentage of users was evaluated in the goals at admission and at the end of the study. RESULTS: Exported, converted and validated data of 1,977 users with average follow-up time of 21 months. Of these, 51.4% were men, 58% were > 64 years of age and 81.6% were overweight. The main medications in use were diuretics (82.9%), BRAT (62%), Statin (60.7%) and ACE inhibitors (49.9%). The percentage of users with a decline in the glomerular filtration rate was 33.7%. Regarding glycated hemoglobin, users with CKD and DM, 36% were within the initial goal and 52.1% of the final. Blood pressure was at the target for admission at 34.3% and 49.8% at the end of follow-up. CONCLUSION: Validated data are of vital importance for health managers to monitor users. The population of this study is predominantly elderly, obese, requiring multi-professional care to slow the progression of the disease and decrease morbidity and mortality.

Validated registry of pre-dialysis chronic kidney disease: description of a large cohort / Registro validado de doença renal crônica pré-dialítica: descrição de uma grande coorte

ABSTRACT Introduction: Chronic diseases account for the majority of deaths in Brazil. These include hypertension (SAH) and diabetes mellitus (DM), which are the main causes of chronic kidney disease (CKD). Objective: This study aimed to validate the data of an electronic health record and to point out characteristics of the profile of these users in relation to clinical quality indicators for a pre-dialytic CKD. Methods: Retrospective cohort, August/2010 to December/2014. Included users > 18 years, with at least two queries. Variables analyzed: sociodemographic, underlying disease, main medications and main clinical indicators of control. A descriptive analysis was performed and the percentage of users was evaluated in the goals at admission and at the end of the study. Results: Exported, converted and validated data of 1,977 users with average follow-up time of 21 months. Of these, 51.4% were men, 58% were > 64 years of age and 81.6% were overweight. The main medications in use were diuretics (82.9%), BRAT (62%), Statin (60.7%) and ACE inhibitors (49.9%). The percentage of users with a decline in the glomerular filtration rate was 33.7%. Regarding glycated hemoglobin, users with CKD and DM, 36% were within the initial goal and 52.1% of the final. Blood pressure was at the target for admission at 34.3% and 49.8% at the end of follow-up. Conclusion: Validated data are of vital importance for health managers to monitor users. The population of this study is predominantly elderly, obese, requiring multi-professional care to slow the progression of the disease and decrease morbidity and mortality.

RESUMO Introdução: As doenças crônicas são responsáveis pela maioria dos óbitos no Brasil. Estas incluem hipertensão (HAS) e diabetes mellitus (DM), que figuram como as principais causas de doença renal crônica (DRC). Objetivo: Este estudo teve como objetivo validar os dados de um sistema de prontuário eletrônico e apontar características do perfil dos usuários em relação aos indicadores clínicos de qualidade para DRC pré-dialítica. Métodos: Estudo observacional retrospectivo cobrindo o período de agosto de 2010 a dezembro de 2014. Foram incluídos indivíduos maiores de 18 anos, com pelo menos duas buscas. Variáveis analisadas: sociodemográficas, doença de base, principais medicamentos e principais indicadores clínicos de controle. Foi realizada uma análise descritiva e avaliado o percentual de usuários dentro das metas na internação e ao final do estudo. Resultados: Foram exportados, convertidos e validados os dados de 1.977 usuários com tempo médio de seguimento de 21 meses. Destes, 51,4% eram homens, 58% tinham idade superior a 64 anos e 81,6% apresentavam sobrepeso. Os principais medicamentos em uso foram diuréticos (82,9%), BRAT (62%), estatina (60,7%) e inibidores da ECA (49,9%). O percentual de usuários com queda da taxa de filtração glomerular foi de 33,7%. Em relação à hemoglobina glicada, dos usuários com DRC e DM, 36% estavam dentro da meta inicial e 52,1% da final. A pressão arterial estava dentro do alvo em 34,3% dos pacientes na internação e em 49,8% ao final do seguimento. Conclusão: Dados validados são de vital importância para os gestores da saúde monitorarem os usuários. A população deste estudo é predominantemente idosa, obesa, e com necessidade de cuidados multiprofissionais para retardar a progressão da doença e diminuir a morbimortalidade.